XTRA:NN6

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally.


Snowflake Analysis

Adequate balance sheet and overvalued.

Share Price & News

How has NanoRepro's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NN6's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.1%

NN6

2.0%

DE Medical Equipment

0.7%

DE Market


1 Year Return

36.5%

NN6

23.5%

DE Medical Equipment

8.8%

DE Market

Return vs Industry: NN6 exceeded the German Medical Equipment industry which returned 23.4% over the past year.

Return vs Market: NN6 exceeded the German Market which returned 8.1% over the past year.


Shareholder returns

NN6IndustryMarket
7 Day10.1%2.0%0.7%
30 Day26.8%1.7%0.1%
90 Day-35.5%-1.7%12.6%
1 Year36.5%36.5%25.2%23.5%11.2%8.8%
3 Year-13.1%-15.0%143.1%137.5%5.4%-3.0%
5 Year23.1%20.3%240.3%226.6%15.9%0.3%

Price Volatility Vs. Market

How volatile is NanoRepro's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is NanoRepro undervalued compared to its fair value and its price relative to the market?

2.72x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NN6's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NN6's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NN6 is unprofitable, so we can't compare its PE Ratio to the DE Medical Equipment industry average.

PE vs Market: NN6 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NN6's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NN6 is good value based on its PB Ratio (2.7x) compared to the DE Medical Equipment industry average (4.9x).


Next Steps

Future Growth

How is NanoRepro forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NanoRepro has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has NanoRepro performed over the past 5 years?

-8.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NN6 is currently unprofitable.

Growing Profit Margin: NN6 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NN6 is unprofitable, and losses have increased over the past 5 years at a rate of 8.6% per year.

Accelerating Growth: Unable to compare NN6's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NN6 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.6%).


Return on Equity

High ROE: NN6 has a negative Return on Equity (-26.84%), as it is currently unprofitable.


Next Steps

Financial Health

How is NanoRepro's financial position?


Financial Position Analysis

Short Term Liabilities: NN6's short term assets (€1.8M) exceed its short term liabilities (€374.2K).

Long Term Liabilities: NN6 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: NN6's debt to equity ratio (4.5%) is considered satisfactory.

Reducing Debt: NN6's debt to equity ratio has reduced from 6.3% to 4.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NN6 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NN6 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 4.5% each year


Next Steps

Dividend

What is NanoRepro current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NN6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NN6's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NN6's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NN6's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NN6's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Lisa Jüngst

no data

Tenure

Ms. Lisa Jüngst serves as President of the Management Board at NanoRepro AG and has been its Member of Management Board since April 2013. She is Chief Executive Officer at NanoRepro AG. Ms. Jüngst served ...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10%.


Top Shareholders

Company Information

NanoRepro AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NanoRepro AG
  • Ticker: NN6
  • Exchange: XTRA
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €13.063m
  • Shares outstanding: 9.33m
  • Website: https://www.nanorepro.com

Number of Employees


Location

  • NanoRepro AG
  • Untergasse 8
  • Marburg
  • Hessen
  • 35037
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NN6DB (Deutsche Boerse AG)YesShare CapitalDEEUROct 2008
NN6XTRA (XETRA Trading Platform)YesShare CapitalDEEUROct 2008

Biography

NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family pl ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/10 21:55
End of Day Share Price2020/08/10 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.